# Study to Evaluate Biomarkers and Safety of Dapagliflozin Concomitant with Neoadjuvant Therapy

> **NCT05989347** · PHASE1 · RECRUITING · sponsor: **Yale University** · enrollment: 20 (estimated)

## Conditions studied

- Breast Cancer
- Hyperinsulinism
- HER2-negative Breast Cancer

## Interventions

- **DRUG:** Dapagliflozin 10mg

## Key facts

- **NCT ID:** NCT05989347
- **Lead sponsor:** Yale University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-15
- **Primary completion:** 2025-12
- **Final completion:** 2025-12
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05989347

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05989347, "Study to Evaluate Biomarkers and Safety of Dapagliflozin Concomitant with Neoadjuvant Therapy". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05989347. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*